Boehringer Ingelheim

Boehringer Ingelheim | May 16, 2017

Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology....

Boehringer Ingelheim | August 25, 2017

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3) (1), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH....

Boehringer Ingelheim | November 03, 2017

Boehringer Ingelheim has linked with US group Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases....

Boehringer Ingelheim | November 09, 2017

The German drugmaker is linking with UK-based MiNA Therapeutics to develop novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (siRNA) therapeutics platform....